TY - JOUR
T1 - Discovering biomarkers for antidepressant response
T2 - Protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort
AU - and on behalf of the CAN-BIND Investigator Team
AU - Lam, Raymond W.
AU - Milev, Roumen
AU - Rotzinger, Susan
AU - Andreazza, Ana C.
AU - Blier, Pierre
AU - Brenner, Colleen
AU - Daskalakis, Zafiris J.
AU - Dharsee, Moyez
AU - Downar, Jonathan
AU - Evans, Kenneth R.
AU - Farzan, Faranak
AU - Foster, Jane A.
AU - Frey, Benicio N.
AU - Geraci, Joseph
AU - Giacobbe, Peter
AU - Feilotter, Harriet E.
AU - Hall, Geoffrey B.
AU - Harkness, Kate L.
AU - Hassel, Stefanie
AU - Ismail, Zahinoor
AU - Leri, Francesco
AU - Liotti, Mario
AU - MacQueen, Glenda M.
AU - McAndrews, Mary Pat
AU - Minuzzi, Luciano
AU - Müller, Daniel J.
AU - Parikh, Sagar V.
AU - Placenza, Franca M.
AU - Quilty, Lena C.
AU - Ravindran, Arun V.
AU - Salomons, Tim V.
AU - Soares, Claudio N.
AU - Strother, Stephen C.
AU - Turecki, Gustavo
AU - Vaccarino, Anthony L.
AU - Vila-Rodriguez, Fidel
AU - Kennedy, Sidney H.
N1 - Funding Information:
CAN-BIND is an Integrated Discovery Program carried out in partnership with, and financial support from, the Ontario Brain Institute, an independent non-profit corporation, funded partially by the Ontario government. The opinions, results and conclusions are those of the authors and no endorsement by the Ontario Brain Institute is intended or should be inferred. Additional funding is provided by the Canadian Institutes of Health Research (CIHR), Lundbeck, Bristol-Myers Squibb,, and Servier. Funding and/or in kind support is also provided by the investigators’ universities and academic institutions. All study medications are independently purchased at wholesale market values. Members of the CAN-BIND Investigator Team are listed here: www.canbind.ca/ our-team/.
Publisher Copyright:
© 2016 Lam et al.
PY - 2016/4/16
Y1 - 2016/4/16
N2 - Background: Major Depressive Disorder (MDD) is among the most prevalent and disabling medical conditions worldwide. Identification of clinical and biological markers ("biomarkers") of treatment response could personalize clinical decisions and lead to better outcomes. This paper describes the aims, design, and methods of a discovery study of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker Integration Network in Depression (CAN-BIND). The CAN-BIND research program investigates and identifies biomarkers that help to predict outcomes in patients with MDD treated with antidepressant medication. The primary objective of this initial study (known as CAN-BIND-1) is to identify individual and integrated neuroimaging, electrophysiological, molecular, and clinical predictors of response to sequential antidepressant monotherapy and adjunctive therapy in MDD. Methods: CAN-BIND-1 is a multisite initiative involving 6 academic health centres working collaboratively with other universities and research centres. In the 16-week protocol, patients with MDD are treated with a first-line antidepressant (escitalopram 10-20 mg/d) that, if clinically warranted after eight weeks, is augmented with an evidence-based, add-on medication (aripiprazole 2-10 mg/d). Comprehensive datasets are obtained using clinical rating scales; behavioural, dimensional, and functioning/quality of life measures; neurocognitive testing; genomic, genetic, and proteomic profiling from blood samples; combined structural and functional magnetic resonance imaging; and electroencephalography. De-identified data from all sites are aggregated within a secure neuroinformatics platform for data integration, management, storage, and analyses. Statistical analyses will include multivariate and machine-learning techniques to identify predictors, moderators, and mediators of treatment response. Discussion: From June 2013 to February 2015, a cohort of 134 participants (85 outpatients with MDD and 49 healthy participants) has been evaluated at baseline. The clinical characteristics of this cohort are similar to other studies of MDD. Recruitment at all sites is ongoing to a target sample of 290 participants. CAN-BIND will identify biomarkers of treatment response in MDD through extensive clinical, molecular, and imaging assessments, in order to improve treatment practice and clinical outcomes. It will also create an innovative, robust platform and database for future research. Trial registration: ClinicalTrials.gov identifier NCT01655706. Registered July 27, 2012.
AB - Background: Major Depressive Disorder (MDD) is among the most prevalent and disabling medical conditions worldwide. Identification of clinical and biological markers ("biomarkers") of treatment response could personalize clinical decisions and lead to better outcomes. This paper describes the aims, design, and methods of a discovery study of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker Integration Network in Depression (CAN-BIND). The CAN-BIND research program investigates and identifies biomarkers that help to predict outcomes in patients with MDD treated with antidepressant medication. The primary objective of this initial study (known as CAN-BIND-1) is to identify individual and integrated neuroimaging, electrophysiological, molecular, and clinical predictors of response to sequential antidepressant monotherapy and adjunctive therapy in MDD. Methods: CAN-BIND-1 is a multisite initiative involving 6 academic health centres working collaboratively with other universities and research centres. In the 16-week protocol, patients with MDD are treated with a first-line antidepressant (escitalopram 10-20 mg/d) that, if clinically warranted after eight weeks, is augmented with an evidence-based, add-on medication (aripiprazole 2-10 mg/d). Comprehensive datasets are obtained using clinical rating scales; behavioural, dimensional, and functioning/quality of life measures; neurocognitive testing; genomic, genetic, and proteomic profiling from blood samples; combined structural and functional magnetic resonance imaging; and electroencephalography. De-identified data from all sites are aggregated within a secure neuroinformatics platform for data integration, management, storage, and analyses. Statistical analyses will include multivariate and machine-learning techniques to identify predictors, moderators, and mediators of treatment response. Discussion: From June 2013 to February 2015, a cohort of 134 participants (85 outpatients with MDD and 49 healthy participants) has been evaluated at baseline. The clinical characteristics of this cohort are similar to other studies of MDD. Recruitment at all sites is ongoing to a target sample of 290 participants. CAN-BIND will identify biomarkers of treatment response in MDD through extensive clinical, molecular, and imaging assessments, in order to improve treatment practice and clinical outcomes. It will also create an innovative, robust platform and database for future research. Trial registration: ClinicalTrials.gov identifier NCT01655706. Registered July 27, 2012.
UR - http://www.scopus.com/inward/record.url?scp=84963626506&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963626506&partnerID=8YFLogxK
U2 - 10.1186/s12888-016-0785-x
DO - 10.1186/s12888-016-0785-x
M3 - Article
C2 - 27084692
AN - SCOPUS:84963626506
SN - 1471-244X
VL - 16
JO - BMC Psychiatry
JF - BMC Psychiatry
IS - 1
M1 - 105
ER -